VAL — ValiRx Income Statement
0.000.00%
Last trade - 00:00- £1.87m
- £0.74m
- £0.01m
Annual income statement for ValiRx, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0.01 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 0.008 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2.7 | 1.53 | 1.68 | 2.59 | 2.31 |
| Operating Profit | -2.7 | -1.53 | -1.68 | -2.59 | -2.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.72 | -1.54 | -1.68 | -2.6 | -2.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.43 | -1.47 | -1.55 | -2.41 | -2.13 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.39 | -1.44 | -1.52 | -2.37 | -2.04 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.39 | -1.44 | -1.52 | -2.37 | -2.04 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.311 | -0.038 | -0.023 | -0.031 | -0.02 |